Open

Phase I and Fast Track proposals will be accepted Direct-to-Phase II proposals will not be accepted Number of anticipated awards: 2-3 Budget (total costs): Phase I: $ 300,000 for up to 2 years Phase II: $ 1 million for up to 3 years. Page 105 Background Globally, an estimated 58 million people have chronic hepatitis C virus (HCV) infection, with about 1.5 million new cases occurring per year. Amon ...

Phase I and Fast Track proposals will be accepted Direct-to-Phase II proposals will not be accepted Number of anticipated awards: 4-5 Budget (total costs): Phase I: $ 300,000 for up to 2 years Phase II: $ 1 million for up to 3 years Background An estimated 1.1 million people in the US are living with HIV, and one in seven are unaware of their infection. As a result, they are not accessing the care ...

Phase I or Fast Track proposals will be accepted. Direct-to-Phase II proposals will not be accepted. Number of anticipated awards: 2-3 Budget (total costs): Phase I: $ 300,000 for up to 1 year Phase II: $ 2 million for up to 3 years Background Viral infections due to hepatitis B virus (HBV) and hepatitis C virus (HCV) are major global public health burdens, and account for more than 3.0 million ne ...

Fast-Track proposals will be accepted. Direct-to-phase II proposals will be accepted. Number of anticipated awards: 1-3 Budget (total costs): Phase I: $300,000/year for up to 2 years Phase II: $1,000,000/year with appropriate justification by the applicant for up to 3 years Mission: IID and BIOD COR: Kentner Singleton Background The goal of this program is to support the pre-clinical development o ...

Fast-Track proposals will be accepted Direct-to-phase II proposals will be accepted Number of anticipated awards: 3-5 Mission: IID or BioD or both: both COR: Joy Liu Budget (total costs): Phase I: $300,000/year for up to 2 years Phase II: $1,500,000 with appropriate justification by the applicant for up to 3 years Background This program addresses the limited availability of reagents (e.g., antibo ...

Fast-Track proposals will be accepted Direct-to-phase II proposals will be accepted Number of anticipated awards: 1-3 Mission: BioD COR: Wolfgang Leitner Budget (total costs): Phase I: $300,000/year for up to 2 years Phase II: $1,000,000/year with appropriate justification by the applicant for up to 3 years Background The goal of this program is to support 1) the screening for new vaccine adjuvant ...

Fast-Track proposals will be accepted. Direct-to-Phase II proposals will NOT be accepted. Number of anticipated awards: 2-3 Budget (total costs): Phase I: $300,000 for up to one year; Phase II: $1,500,000 for up to 3 years Background There is an urgent need for new therapeutics products for treating pulmonary diseases caused by mycobacteria. These include tuberculosis (TB), caused by Mycobacterium ...

Fast-Track proposals will be accepted. Direct-to-Phase II proposals will NOT be accepted. Number of anticipated awards: 2-3 Budget (total costs): Phase I: $300,000 for up to one year; Phase II: $1,500,000 for up to 3 years. Background Diagnostics in current use for malaria and specific NTDs (visceral leishmaniasis, lymphatic filariasis, onchocerciasis, schistosomiasis) do not meet the sensitivity ...

(Direct to Phase II proposals will not be accepted) (Fast-Track proposals will be accepted) Number of anticipated awards: 1-2 Budget (total costs): Phase I: $300,000 for up to 1 year; Phase II: $1,500,000 for up to 3 years Page 118 Background Over 60 million people in the U.S. have genital herpes which is caused by infection with herpes simplex virus type 1 or 2 (HSV-1, HSV-2). The WHO’s 2021 gl ...

Fast-Track proposals will be accepted Direct-to-Phase II proposals will be accepted Number of anticipated awards: 2-3 Budget (total costs): Phase I: $300,000 for up to one year; Phase II: $1,500,000 for up to 3 years Background Injectable benzathine penicillin (BPG) is currently the only CDC-recommended first line therapy for treatment of infection with Treponema pallidum (syphilis) in all populat ...